Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type

Journal of Virology

Volumn 70, Issue 6, 1996, Pages 3668-3677

  Klasse, P J ^a,c   Moore, John P ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN;

ARTICLE; CELL ISOLATION; COMPETITIVE INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; QUANTITATIVE ASSAY; VACCINATION; VIRION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CELL LINE; HIV-1; HUMANS; MODELS, BIOLOGICAL; NEUTRALIZATION TESTS;

EID: 0029938480     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Allaway, G. P., K. L. Davis-Bruno, G. A. Beaudry, E. B. Garcia, E. L. Wong, A. M. Ryder, K. W. Hasel, M.-C. Gauduin, R. A. Koup, J. S. McDougal, and P. J. Maddon. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533-539.
2. Andrewes, C. H., and W. J. Elford. 1933. Observations on anti-phage sera. I. "the peicentage law." Br. J. Exp. Pathol. 14:367-376.
3. Ashkenazi, A., D. H. Smith, S. A. Marsters, L. Riddle, T. J. Gregory, D. D. Ho, and D. J. Capon. 1991. Resistance of primary HIV-1 isolates to soluble CD4 is independent of CD4-gp120 binding affinity. Proc. Natl. Acad. Sci. USA 88:7056-7060.
4. Atkins, P. W. 1986. Physical chemistry, 3rd ed., p. 687-712. Oxford University Press, New York.
5. Baldinotti, F., D. Matteucci, P. Mazzelli, C. Giannelli, P. Bandecchi, F. Tozzini, and M. Bendinelli. 1994. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J. Virol. 68:4572-4579.
6. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Herman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013.
7. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
8. Cook, R. F., S. L. Berger, K. E. Rushlow, J. M. McManus, S. J. Cook, S. Harold, M. L. Raabe, R. C. Montelaro, and C. J. Issel. 1995. Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anaemia virus linked to amino acid substitutions in the surface unit envelope glycoprotein. J. Virol. 69:1493-1499.
9. Creighton, T. E. 1993. Proteins, 2nd ed. W. H. Freeman & Co., New York.
10. Daar, E. S., X. L. Li, T. Moudgil, and D. D. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87:6574-6578.
11. Della-Porta, A. J., and E. G. Westaway. 1977. A multi-hit model for the neutralization of animal viruses. J. Gen. Virol. 38:1-19.
12. Dimmock, N. J. 1993. The neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183:71-73.
13. Dulbecco, R., M. Vogt, and A. G. R. Slrickland. 1956. A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. Virology 2:162-205.
14. Eason, G., C. W. Coles, and G. Gettinby. 1980. Mathematics and statistics for the biosciences. Ellis Horwood Limited, Chichester, England.
15. Gelderblom, H. R. 1991. Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 5:617-638.
16. Groenink, M., J. P. Moore, S. Broersen, and H. Shuitemaker. 1995. Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J. Virol. 69:523-527.
17. Icenogle, J., H. Shiwen, G. Duke, S. Gilbert, R. Rueckert, and J. Anderegg. 1983 Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 127:412-425.
18. Rabat, D., S. L. Kozak, K. Wehrly, and B. Chesebro. 1994. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 68:2570-2577.
19. Karush, F. 1978. Affinity and the law of mass action, p. 181-197. In R. A. Good and S. B. Day (ed.), Comprehensive immunology. Plenum Press, New York.
20. Klasse, P. J., and J. A. McKeating. 1993. Soluble CD4- and CD4-immunoglobulin-selected HIV-1 variants: a phenotypic characterization. AIDS Res. Hum. Retroviruses 9:595-604.
21. Klasse, P. J., J. P. Moore, and B. A. Jameson. 1993. The interplay of the HIV-1 envelope complex, gp120 and gp41, with CD4, p. 241-266. In W. J. W. Morrow and N. L. Haigwood (ed.), HIV molecular organization, pathogenicity and treatment. Elsevier, Amsterdam.
22. Klasse, P. J., and Q. J. Sattentau. Variants of HIV-1-LAI selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS Res. Hum. Retroviruses, in press.
23. Kliks, S. C., T. Shioda, N. L. Haigwood, and J. A. Levy. 1993. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 98:11518-11522.
24. Layne, S. P., M. J. Merges, M. Dembo, J. L. Spouge, S. R. Conley, J. P. Moore, J. L. Raina, H. Renz, H. R. Gelderblom, and P. L. Nara. 1992. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189:695-714.
25. Layne, S. P., M. J. Merges, M. Dembo, J. L. Spouge, and P. L. Nara. 1990. HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (London) 346:277-279.
26. Layne, S. P., M. J. Merges, J. L. Spouge, M. Dembo, and P. L. Nara. 1991. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J. Virol. 65:3293-3300.
27. Layne, S. P., J. L. Spouge, and M. Dembo. 1989. Quantifying the infectivity of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86:4644-4648.
28. Marcon, L., and J. Sodroski. 1994. gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment. J. Virol. 68:1977-1982.
29. McKeating, J. A., A. McKnight, and J. P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65:852-860.
30. McLain, L., and N. J. Dimmock. 1994. Single-hit and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 75:1457-1460.
31. Moore, J. P. 1990. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS 4:297-305.
32. Moore, J. P., L. C. Burkly, R. I. Connor, V. Cao, R. Tizard, D. D. Ho, and R. A. Fisher. 1993. Adaptation of two primary immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res. Hum. Retroviruses 9:529-539.
33. Moore, J. P., Y. Cao, L. Qing, Q. J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C. F. Barbas III, D. R. Burton, and D. D. Ho. 1995. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:101-109.
34. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
35. Moore, J. P., and P. J. Klasse. 1991. Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation. AIDS Res. Hum. Retroviruses 8:443-450.
36. Moore, J. P., J. A. McKeating, Y. Huang, A. Ashkenazi, and D. D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
37. Moore, J. P., Q. J. Sattentau, P. J. Klasse, and L. C. Burkly. 1992. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoprotcins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD44 cells. J. Virol. 66:4784-4793.
38. Moore, J. P., Q. J. Sattentau, R. Wyatt, and J. Sodroski. 1994. Probing the structure of the glycoprotein gp120 of human immunodeficiency virus type 1 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
39. O'Brien, W. A., S.-H. Mao, Y. Cao, and J. P. Moore. 1994. Macrophagetropic and T-ccll line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J. Virol. 68:5264-5269.
40. Poignard, P., T. Fouts, D. Naniche, J. P. Moore, and Q. J. Sattentau. Neutralizing antibodies to human immunodeficiency virus type 1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med., in press.
41. Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, R. Predl, F. Sleindl, C. Tauer, R. Berger, N. Barren, A. Jungbauer, and H. Katinger. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruscs 10:1651-1658.
42. Roben, P., J. P. Moore, M. Thali, J. Sodroski, C. F. Barbas III, and D. R. Burton. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
43. Sattentau, Q. J., and J. P. Moore. 1995. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the glycoprotein gp120 oligomer. J. Exp. Med. 182:185-196.
44. Saitentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Exposed and masked epitopes on functional, oligomeric gp41 molecules. Virology 206: 713-717.
45. Sawyer, L. S., M. T. Wrin, L. Crawford-Miksza, B. Potts, Y. Wu, P. A. Weber, R. D. Alfonso, and C. V. Hanson. 1994. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J. Virol. 68:1342-1349.
46. Schutten, M., A. C. Andeweg, M. L. Bosch, and A. D. M. E. Osterhaus. 1995. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 41:18-22.
47. Smith, D. H., R. A. Byrn, S. A. Marsters, T. Gregory, J. E. Groopman, and D. J. Capon. 1987. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 238:1704-1707.
48. Spouge, J. L. 1994. Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies. J. Virol. 68:1782-1789, 1994.
49. Stamatatos, L., A. Werner, and C. Cheng-Mayer. 1994. Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J. Virol. 68:4973-4979.
50. Sullivan, N., Y. Sun, J. Li, W. Hoffmann, and J. Sodroski. 1995. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69:4413-4422.
51. Taylor, H. P., S. J. Armstrong, and N. J. Dimmock. 1987. Quantitative relationships between an influenza virus and neutralizing antibody. Virology 159:288-298.
52. Weiss, R. A., P. R. Clapham, J. N. Weber, A. G. Dalgleish, L. A. Lasky, and P. W. Berman. 1986. Variable and conserved neutralisation antigens of human immunodeficiency virus. Nature (London) 324:572-575.
53. Wrin, T., T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. H. Nunberg. 1995. Adaptation to growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48.